MAPT and Alzheimer disease: The combination of CSF traditional biomarkers (e.g., Aβ1–42/Aβ1–40 ratio, t-tau/Aβ1–42, and p-tau/Aβ1–42 ratios) can improve the diagnostic accuracy as well as the prediction of cognitive decline in AD patients.